KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to -$1.16.

  • Halozyme Therapeutics' EPS (Basic) fell 20740.74% to -$1.16 in Q4 2025 from the same period last year, while for Dec 2025 it was $2.65, marking a year-over-year decrease of 2428.57%. This contributed to the annual value of $2.64 for FY2025, which is 2457.14% down from last year.
  • Latest data reveals that Halozyme Therapeutics reported EPS (Basic) of -$1.16 as of Q4 2025, which was down 20740.74% from $1.49 recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' EPS (Basic) registered a high of $1.53 during Q3 2021, and its lowest value of -$1.16 during Q4 2025.
  • In the last 5 years, Halozyme Therapeutics' EPS (Basic) had a median value of $0.62 in 2023 and averaged $0.63.
  • Per our database at Business Quant, Halozyme Therapeutics' EPS (Basic) skyrocketed by 60000.0% in 2021 and then plummeted by 20740.74% in 2025.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' EPS (Basic) stood at $0.47 in 2021, then dropped by 8.51% to $0.43 in 2022, then soared by 51.16% to $0.65 in 2023, then skyrocketed by 66.15% to $1.08 in 2024, then tumbled by 207.41% to -$1.16 in 2025.
  • Its EPS (Basic) was -$1.16 in Q4 2025, compared to $1.49 in Q3 2025 and $1.36 in Q2 2025.